GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Provectus Biopharmaceuticals Inc (OTCPK:PVCT) » Definitions » PEG Ratio

PVCT (Provectus Biopharmaceuticals) PEG Ratio : 0.00 (As of Mar. 26, 2025)


View and export this data going back to 1997. Start your Free Trial

What is Provectus Biopharmaceuticals PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Provectus Biopharmaceuticals's PE Ratio without NRI is 0.00. Provectus Biopharmaceuticals's 5-Year EBITDA growth rate is 15.10%. Therefore, Provectus Biopharmaceuticals's PEG Ratio for today is 0.00.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Provectus Biopharmaceuticals's PEG Ratio or its related term are showing as below:



PVCT's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.44
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Provectus Biopharmaceuticals PEG Ratio Historical Data

The historical data trend for Provectus Biopharmaceuticals's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Provectus Biopharmaceuticals PEG Ratio Chart

Provectus Biopharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Provectus Biopharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Provectus Biopharmaceuticals's PEG Ratio

For the Biotechnology subindustry, Provectus Biopharmaceuticals's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Provectus Biopharmaceuticals's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's PEG Ratio falls into.



Provectus Biopharmaceuticals PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Provectus Biopharmaceuticals's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/15.10
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Provectus Biopharmaceuticals  (OTCPK:PVCT) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Provectus Biopharmaceuticals PEG Ratio Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Provectus Biopharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
800 S Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes (HXs). Its HX molecule is named rose bengal sodium. The Company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient in the drug product candidates of its current clinical development programs and the preclinical formulations of its current drug discovery programs.
Executives
Jeffrey Allen Morris 10 percent owner 1729 TRIANGLE PARK DR., MARYVILLE TN 37801
Webster Bailey director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Heather Raines officer: Chief Financial Officer 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
Edward Pershing director 2220 SOUTHERLAND AVE, KNOXVILLE TN 37919
John Iii Lacy director 10025 INVESTMENT DRIVE, SUITE 250, KNOXVILLE TN 37932
John R Glass officer: See Remarks 7327 OAK RIDGE HIGHWAY SUITE A, KNOXVILLE TN 37931
Bruce Horowitz director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Dominic Rodrigues director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Peter R Culpepper officer: Interim CEO, CFO, COO 7327 OAK RIDGE HWY, SUITE A, OAK RIGE TN 37931
Eric Phd Wachter director, officer: Chief Technology Officer PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Jan Koe director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Smith Alfred E. Iv director 191 MAIN STREET, NEW CANAAN CT 06840
Kelly M Mcmasters director 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931
Donald E Adams 10 percent owner 370 CRESTMONT DRIVE, SAN LUIS OBISPO CA 93401
Timothy Phd Scott director, 10 percent owner, officer: President PROVECTUS PHARMACEUTICALS INC, 7327 OAK RIDGE HIGHWAY, KNOXVILLE TN 37931

Provectus Biopharmaceuticals Headlines

From GuruFocus